This Cooperative Research Center proposal is unique in that the proposed projects will almost? exclusively involve human subjects. To best accomplish these protocols, this Core has been established? specifically for the purpose of recruiting potential subjects and performing screening evaluations to determine? their eligibility for inclusion in these studies. The proposed projects will involve two distinct groups of? patients. The first will focus on patients allergic to cat allergen, who will be included in the nasal challenge,? bronchial challenge, and cat room challenge protocols. These subjects will be recruited either from existing? patient databases or by advertisement and will undergo a detailed baseline evaluation in this Core, including? skin testing to cat and other common environmental allergens, spirometry, methacholine challenge,? measurement of total and allergen-specific serum IgE levels and histamine releasing factor, blood basophil? studies, and nasal challenge with cat allergen. Those who meet the inclusion and exclusion criteria as? detailed in the protocols will be invited to participate in one or more of those studies. The second group of? patients will include those with a known allergy to milk, egg, or peanut. They will also be recruited from? existing patient databases or by advertisement. Their evaluation will include skin testing to the relevant food? allergen(s) and environmental allergens, spirometry, measurement of total and allergen-specific serum IgE? levels and histamine releasing factor, blood basophil studies, and double-blind, placebo-controlled food? challenges to the food(s) in question. Those who meet the inclusion and exclusion criteria as detailed in the? protocol will be invited to participate in the food challenge study.? In addition to its role in the recruitment and evaluation of potential study subjects, this Core will? assume primary responsibility for the Center for issues regarding patient safety and regulatory affairs. For? this reason, the Core's personnel include a regulatory affairs specialist who will meet regularly with the? principal investigator to oversee these issues and serve as a liaison between the Center, the IRB, and the? FDA.
| MacGlashan Jr, Donald (2016) Stability of Syk protein and mRNA in human peripheral blood basophils. J Leukoc Biol 100:535-43 |
| Sterba, Patricia M; Hamilton, Robert G; Saini, Sarbjit S (2015) Suppression of basophil Fc?RI activation by serum from active chronic idiopathic/spontaneous urticaria (CIU/CSU) subjects. J Invest Dermatol 135:1454-1456 |
| Narisety, Satya D; Frischmeyer-Guerrerio, Pamela A; Keet, Corinne A et al. (2015) A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy. J Allergy Clin Immunol 135:1275-82.e1-6 |
| Gorelik, Mark; Narisety, Satya D; Guerrerio, Anthony L et al. (2015) Suppression of the immunologic response to peanut during immunotherapy is often transient. J Allergy Clin Immunol 135:1283-92 |
| McGowan, Emily C; Savage, Jessica H; Courneya, Jean-Paul et al. (2014) Relationship of IgE to basophil phenotypes in peanut-sensitized adults. J Allergy Clin Immunol 134:746-749.e6 |
| Macglashan Jr, Donald W; Saini, Sarbjit S (2013) Omalizumab increases the intrinsic sensitivity of human basophils to IgE-mediated stimulation. J Allergy Clin Immunol 132:906-11.e1-4 |
| MacGlashan Jr, Donald W (2012) IgE-dependent signaling as a therapeutic target for allergies. Trends Pharmacol Sci 33:502-9 |
| Savage, Jessica H; Courneya, Jean-Paul; Sterba, Patricia M et al. (2012) Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy. J Allergy Clin Immunol 130:1123-1129.e2 |
| MacGlashan Jr, Donald W; Savage, Jessica H; Wood, Robert A et al. (2012) Suppression of the basophil response to allergen during treatment with omalizumab is dependent on 2 competing factors. J Allergy Clin Immunol 130:1130-1135.e5 |
| Frischmeyer-Guerrerio, Pamela A; Schroeder, John T (2012) Cellular immune response parameters that influence IgE sensitization. J Immunol Methods 383:21-9 |
Showing the most recent 10 out of 34 publications
